Stay updated on FGF401 in HCC and Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the FGF401 in HCC and Solid Tumors Clinical Trial page.

Latest updates to the FGF401 in HCC and Solid Tumors Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision.SummaryDifference2%

- Check25 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0, indicating a newer release.SummaryDifference0.1%

- Check40 days agoChange DetectedUpdated page revision from v3.0.1 to v3.0.2, indicating a small update to content or features. The 'Back to Top' navigation element was removed.SummaryDifference0.1%

- Check47 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.1%

- Check54 days agoChange DetectedThe web page has undergone significant updates, including the addition of new facility names and locations across various countries, while also removing several previous location entries. Notably, the drug names 'roblitinib' and 'spartalizumab' have been retained, indicating a focus on specific treatments.SummaryDifference3%

- Check68 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%

Stay in the know with updates to FGF401 in HCC and Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FGF401 in HCC and Solid Tumors Clinical Trial page.